ESMO 2025: The KEYNOTE-905 trial
- 28-10-2025
- Bladder Cancer
- Expert Interview
- Video
Prof. Christof Vulsteke shares study findings that position perioperative enfortumab vedotin plus pembrolizumab as a new option for cisplatin-ineligible muscle-invasive bladder cancer.